S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
NYSE:EHAB

Enhabit (EHAB) Stock Forecast, Price & News

$12.22
+0.22 (+1.83%)
(As of 09/20/2023 ET)
Compare
Today's Range
$11.93
$12.41
50-Day Range
$11.32
$14.42
52-Week Range
$10.51
$16.64
Volume
438,294 shs
Average Volume
615,639 shs
Market Capitalization
$612.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.29

Enhabit MarketRank™ Forecast

Analyst Rating
Reduce
1.78 Rating Score
Upside/​Downside
16.9% Upside
$14.29 Price Target
Short Interest
Healthy
10.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
-12.50%
From $0.32 to $0.28 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.16 out of 5 stars

Medical Sector

934th out of 962 stocks

Home Health Care Services Industry

7th out of 7 stocks


EHAB stock logo

About Enhabit (NYSE:EHAB) Stock

Enhabit, Inc. is a leading healthcare provider that offers Medicare-certified skilled home health and hospice services in the United States. The company operates in two segments: Home Health and Hospice, providing services to adult patients needing care, including skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Enhabit's hospice services include in-home services to terminally ill patients and their families to address patients' physical needs, including pain control and symptom management, and emotional and spiritual support.

Enhabit operates home health agencies in approximately 34 states, with a concentration in the southern half of the United States. As of March 31, 2022, Enhabit operates in 252 home health agencies and 99 hospice agencies across 34 states. Enhabit provides practices to treat chronic diseases and conditions, including diabetes, arthritis, hypertension,  Alzheimer's disease, spinal stenosis, low vision,  Parkinson's disease, complex wound care, osteoporosis, and chronic pain, along with disease-specific plans for patients with diabetes, post-orthopedic surgery or injury, congestive heart failure,  and respiratory diseases.

Enhabit started as HealthSouth, founded in 1984 by Beam Scrushy and Richard Scrushy. In the early 2000s, the company restructured and rebranded into Encompass Health after being caught up in an accounting scandal. In Q2 of 2022, Enhabit, the healthcare and hospice division, became an independent public company, having completed its spinoff from Encompass Health Corporation. 

Barb Jacobsmeyer was named President and CEO of Enhabit Home Health & Hospice in June 2021. Jacobsmeyer came to Enhabit from Encompass Health, where she served as the company's executive vice president of operations. 

In Q3 of 2022, Enhabit, Inc. announced the acquisition of Caring Hearts Hospice, a locally-owned hospice agency in Texas. The acquisition adds four hospice locations in Texas to Enhabit's existing presence in the state. Ehnabit continues to expand, setting aside approximately one hundred million dollars to fund future mergers and acquisitions. 

Enhabit, Inc. is committed to providing high-quality care and service to patients and their families, and its success is a testament to its dedicated team of healthcare professionals. Enhabit is well-positioned to meet the growing demand for healthcare services in the United States as a leading home health and hospice service provider. With its focus on patient care and commitment to excellence, Enhabit is poised to continue to grow and succeed in the years ahead.

Enhabit's commitment to quality care has not gone unnoticed, as they have received numerous awards and recognitions for their services. In 2021, they were named a HomeCare Elite Top Agency for the 15th year. This recognition is given to the top-performing home health agencies in the United States. They have also received a 5-star rating from the Centers for Medicare & Medicaid Services (CMS) for their home health services, indicating their high quality and patient satisfaction.

Enhabit's success can be attributed to its skilled and compassionate staff and dedication to providing comprehensive and individualized patient care. Enhabit also recognizes the importance of emotional and spiritual support for their patients and their families, particularly in hospice care. Their hospice services include pain and symptom management, spiritual counseling, palliative and dietary counseling, social worker visits, and bereavement counseling services to meet terminally ill patients and their families' individual physical, spiritual, emotional, and psychosocial needs.

EHAB Price History

EHAB Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Goldman Sachs Sticks to Its Hold Rating for Enhabit, Inc (EHAB)
Calculating The Fair Value Of Enhabit, Inc. (NYSE:EHAB)
Bank of America Securities Remains a Sell on Enhabit, Inc (EHAB)
Q2 2023 Enhabit Inc Earnings Call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Enhabit (EHAB) Lags Q2 Earnings and Revenue Estimates
Enhabit: Q2 Earnings Snapshot
Enhabit Reports Second Quarter 2023 Financial Results
SVB Securities Initiates a Sell Rating on Enhabit, Inc (EHAB)
See More Headlines
Receive EHAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enhabit and its competitors with MarketBeat's FREE daily newsletter.

EHAB Company Calendar

Last Earnings
8/09/2023
Today
9/20/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
11,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.29
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+16.9%
Consensus Rating
Reduce
Rating Score (0-4)
1.78
Research Coverage
9 Analysts

Profitability

Net Income
$-40,400,000.00
Pretax Margin
-15.74%

Debt

Sales & Book Value

Annual Sales
$1.08 billion
Cash Flow
$4.30 per share
Book Value
$15.52 per share

Miscellaneous

Free Float
49,150,000
Market Cap
$612.22 million
Optionable
Not Optionable
Beta
1.15
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Ms. Barbara Ann Jacobsmeyer B.S. (Age 57)
    M.A., P.T., Pres, CEO & Director
    Comp: $1.26M
  • Ms. Crissy Buchanan Carlisle (Age 50)
    Exec. VP & CFO
    Comp: $611.66k
  • Ms. Tanya R. Marion (Age 49)
    Chief HR Officer
    Comp: $445.86k
  • Ms. Julie D. Jolley B.S.N. (Age 51)
    R.N., Exec. VP of Home Health & Hospice Operations
    Comp: $642.65k
  • Ms. Jeanne Kalvaitis B.S.N. (Age 66)
    R.N., Exec. VP of Hospice Operations
    Comp: $288.38k
  • Mark Brewer
    Chief Investor Relations Officer
  • Mr. Dylan C. Black (Age 54)
    Gen. Counsel & Sec.
  • Mr. Ronald L. Langham Jr. (Age 46)
    M.B.A., P.T., Exec. VP of Clinical Excellence & Strategy













EHAB Stock - Frequently Asked Questions

Should I buy or sell Enhabit stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enhabit in the last year. There are currently 3 sell ratings, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" EHAB shares.
View EHAB analyst ratings
or view top-rated stocks.

What is Enhabit's stock price forecast for 2023?

9 Wall Street analysts have issued twelve-month price objectives for Enhabit's shares. Their EHAB share price forecasts range from $10.00 to $18.00. On average, they predict the company's stock price to reach $14.29 in the next year. This suggests a possible upside of 16.9% from the stock's current price.
View analysts price targets for EHAB
or view top-rated stocks among Wall Street analysts.

How have EHAB shares performed in 2023?

Enhabit's stock was trading at $13.16 at the beginning of 2023. Since then, EHAB shares have decreased by 7.1% and is now trading at $12.22.
View the best growth stocks for 2023 here
.

Are investors shorting Enhabit?

Enhabit saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 5,270,000 shares, a decline of 7.5% from the August 15th total of 5,700,000 shares. Based on an average daily volume of 715,400 shares, the days-to-cover ratio is presently 7.4 days. Currently, 10.7% of the company's stock are sold short.
View Enhabit's Short Interest
.

When is Enhabit's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our EHAB earnings forecast
.

How were Enhabit's earnings last quarter?

Enhabit, Inc. (NYSE:EHAB) released its quarterly earnings data on Wednesday, August, 9th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.14 by $0.10. The business earned $262.30 million during the quarter, compared to the consensus estimate of $271.48 million. Enhabit had a positive trailing twelve-month return on equity of 4.18% and a negative net margin of 5.19%.

What guidance has Enhabit issued on next quarter's earnings?

Enhabit issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of $0.28-$0.46 for the period, compared to the consensus estimate of $0.65. The company issued revenue guidance of $1.06 billion-$1.06 billion, compared to the consensus revenue estimate of $1.11 billion.

What is Enhabit's stock symbol?

Enhabit trades on the New York Stock Exchange (NYSE) under the ticker symbol "EHAB."

Who are Enhabit's major shareholders?

Enhabit's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.29%), Jana Partners LLC (4.94%), AREX Capital Management LP (4.56%), Cruiser Capital Advisors LLC (4.11%), Paradice Investment Management LLC (4.02%) and State Street Corp (3.93%). Insiders that own company stock include Barbara Ann Jacobsmeyer, Charles M Elson, Erin Hoeflinger, Gregory S Rush, Jeffrey Bolton, John E D D S Maupin Jr, L Edward Shaw Jr, Leo I Higdon Jr, Ronald Leroy Langham Jr and Tanya Renee Marion.
View institutional ownership trends
.

How do I buy shares of Enhabit?

Shares of EHAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enhabit's stock price today?

One share of EHAB stock can currently be purchased for approximately $12.22.

How much money does Enhabit make?

Enhabit (NYSE:EHAB) has a market capitalization of $612.22 million and generates $1.08 billion in revenue each year. The company earns $-40,400,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

How many employees does Enhabit have?

The company employs 11,000 workers across the globe.

How can I contact Enhabit?

The official website for the company is www.ehab.com. The company can be reached via phone at 214-239-6500 or via email at investorrelations@ehab.com.

This page (NYSE:EHAB) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -